safeti immunogen human immunodefici viru type recombin candid vaccin human niaid aid vaccin clinic trial network object safeti immunogen human immunodefici viru type envelop glycoprotein candid vaccin human subject healthi adult seroneg group intervent subject microgram rgp microgram hepat vaccin placebo dose day elect nonblind administr fourth dose day measur main result clinic laboratori toxic follow-up period month effect immun lymphocyt count mitogen respons delayed-typ hypersensit serum antibodi respons hiv envelop protein western blot subject CI dose weakli reactiv intens respons western blot second dose frequenc third dose next month administr fourth dose homolog neutral activ sera subject CI complement-medi antibody-depend enhanc sera subject CI antibodi respons enzyme-link immunosorb assay elisa western blot respons time conclus administr safe high rate antibodi respons western blot administr third fourth dose serum neutral activ complement-medi antibody-depend enhanc subject fourth dose 